Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 24;12:492. doi: 10.3389/fnins.2018.00492

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Qian, Dou, Ruan, He, Zhang and Yan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of ErbB4 siRNA pre-treatment on blood-brain barrier integrity at 24 h after SAH. ErbB4 siRNA aggravated neurological deficits (A) and increased albumin extravasation (B). Representative western blot bands of ErbB4, YAP, PIK3CB, Occludin and Claudin 5 (C). ErbB4 knockdown decreased the expression of ErbB4 ICD/ErbB4 (D), YAP (E), and PIK3CB (F). The increased expression levels of Occludin and Claudin-5 after Nrg1β1 treatment were significantly reduced by ErbB4 depletion (G,H). The PIK3CB specific inhibitor TGX 221 did not affect the expression of ErbB4 ICD/ErbB4 (D), YAP (E) and significantly reduced the expression of PIK3CB (F), Occludin (G) and Claudin-5 (H). n = 6, #p < 0.05 versus SAH + vehicle; @p < 0.05 versus SAH + Nrg1β1; §p < 0.05 versus SAH + Nrg1β1 + ErbB4siRNA.